Shares of Teleflex Incorporated (NYSE:TFX – Get Free Report) have been given an average rating of “Hold” by the twelve research firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, six have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $151.80.
TFX has been the topic of several recent research reports. Royal Bank Of Canada raised shares of Teleflex from a “sector perform” rating to an “outperform” rating and raised their price target for the company from $135.00 to $155.00 in a research report on Friday, May 8th. Piper Sandler reissued an “overweight” rating and set a $169.00 price objective (up from $160.00) on shares of Teleflex in a report on Friday, August 7th. UBS Group increased their price objective on Teleflex from $145.00 to $158.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 11th. Mizuho raised their target price on Teleflex from $140.00 to $145.00 and gave the company a “neutral” rating in a report on Wednesday, July 15th. Finally, Needham & Company LLC raised their target price on Teleflex from $147.00 to $159.00 and gave the company a “buy” rating in a report on Friday, July 31st.
Check Out Our Latest Analysis on Teleflex
Teleflex Stock Up 3.1%
Teleflex (NYSE:TFX – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The medical technology company reported $1.76 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.48. The business had revenue of $570.33 million for the quarter, compared to the consensus estimate of $559.59 million. Teleflex had a positive return on equity of 11.93% and a negative net margin of 39.67%.The firm’s revenue for the quarter was up 28.9% on a year-over-year basis. During the same period in the prior year, the business earned $3.73 EPS. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. As a group, sell-side analysts forecast that Teleflex will post 7.26 earnings per share for the current fiscal year.
Teleflex Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Friday, August 14th will be paid a $0.34 dividend. The ex-dividend date is Friday, August 14th. This represents a $1.36 annualized dividend and a dividend yield of 1.0%. Teleflex’s dividend payout ratio is presently -5.84%.
Hedge Funds Weigh In On Teleflex
Several institutional investors have recently modified their holdings of the business. Kelleher Financial Advisors bought a new stake in Teleflex during the second quarter worth $25,000. Banque Cantonale Vaudoise grew its stake in Teleflex by 82.5% in the 4th quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company’s stock valued at $31,000 after purchasing an additional 113 shares during the period. UMB Bank n.a. grew its stake in Teleflex by 57.1% in the 4th quarter. UMB Bank n.a. now owns 311 shares of the medical technology company’s stock valued at $38,000 after purchasing an additional 113 shares during the period. Allworth Financial LP purchased a new stake in shares of Teleflex during the 2nd quarter valued at $44,000. Finally, Kestra Advisory Services LLC purchased a new stake in shares of Teleflex during the 4th quarter valued at $45,000. 95.62% of the stock is owned by institutional investors.
About Teleflex
Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.
The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.
See Also
- Five stocks we like better than Teleflex
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.
